Neonc Technologies Holdings, Inc. (NTHI)

US — Healthcare Sector
Peers:

Automate Your Wheel Strategy on NTHI

With Tiblio's Option Bot, you can configure your own wheel strategy including NTHI - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol NTHI
  • Rev/Share 0.0057
  • Book/Share -0.5307
  • PB -8.8569
  • Debt/Equity 0.0
  • CurrentRatio 0.4074
  • ROIC 4.785

 

  • MktCap 89425843.0
  • FreeCF/Share -0.3766
  • PFCF -13.092
  • PE -1.7272
  • Debt/Assets 0.0
  • DivYield 0
  • ROE 5.7409

 

  • Rating C
  • Score 2
  • Recommendation Sell
  • P/E Score 1
  • DCF Score 1
  • P/B Score 1
  • D/E Score 1

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
No ratings available.

News

CORRECTING and REPLACING - NeOnc Technologies Holdings, Inc.
NTHI
Published: July 23, 2025 by: GlobeNewsWire
Sentiment: Neutral

CALABASAS, Calif., July 23, 2025 (GLOBE NEWSWIRE) -- In a press release issued earlier today by NeOnc Technologies Holdings, Inc. under the headline, "NeOnc Technologies' Executive Chairman to Be Featured in Live Interview with Kenny Polcari on YouTube.com/@Floorstocks — Today at 11:00 a.m. ET," please note "today" in the headline and first paragraph should be "July 24, 2025." The corrected release follows:

Read More
image for news CORRECTING and REPLACING - NeOnc Technologies Holdings, Inc.
NeOnc Technologies Signs $50 Million Non-Binding Strategic Term Sheet with Quazar Investment to Launch GCC & MENA Expansion and Clinical Trials Platform
NTHI
Published: July 08, 2025 by: GlobeNewsWire
Sentiment: Neutral

CALABASAS, Calif., July 08, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI), a clinical-stage biotechnology company advancing transformative treatments for brain and central nervous system cancers, today announced it has signed a non-binding term sheet with Quazar Investment to form a new UAE-based investment and clinical platform focused on the Middle East and North Africa (MENA) region.

Read More
image for news NeOnc Technologies Signs $50 Million Non-Binding Strategic Term Sheet with Quazar Investment to Launch GCC & MENA Expansion and Clinical Trials Platform
NeOnc Technologies Holdings, Inc. Appoints Dr. Josh Neman as Chief Clinical Officer to Advance Clinical Strategy and Translational Oncology Programs
NTHI
Published: June 06, 2025 by: GlobeNewsWire
Sentiment: Neutral

USC brain tumor authority to accelerate four clinical trials including lead asset NEO100 nearing Phase 2a completion ahead of schedule

Read More
image for news NeOnc Technologies Holdings, Inc. Appoints Dr. Josh Neman as Chief Clinical Officer to Advance Clinical Strategy and Translational Oncology Programs

About Neonc Technologies Holdings, Inc. (NTHI)

  • IPO Date 2025-03-26
  • Website https://www.neonctech.com
  • Industry Biotechnology
  • CEO Thomas C. Chen
  • Employees 8

Neonc Technologies Holdings, Inc. develops novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. Its lead products in development include NEO100, which is in Phase 2a clinical trials for treating glioblastoma; and NEO212, a covalently conjugated molecule combining the chemotherapeutic drug temozolomide with perillyl alcohol that is completed preclinical testing. The company was incorporated in 2023 and is based in Los Angeles, California.